Login to Your Account



Phase III Biogen Clot Factor Gains Long-Lasting 'BeneFIX'

By Randy Osborne
BioWorld Today Contributing Writer

Thursday, September 27, 2012
Would-be competitors coming up quickly behind Biogen Idec Inc.'s Factor IX (rFIXFc) Fc fusion protein, along with an expectation of good news, may have combined to put a Wall Street damper on favorable Phase III results in hemophilia B, as investors looked ahead to Phase III data later this year in the larger market of hemophilia A with a separate molecule, rFVIIIFc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription